Literature DB >> 28011586

Activation of PPAR-α in the early stage of heart failure maintained myocardial function and energetics in pressure-overload heart failure.

Satoshi Kaimoto1, Atsushi Hoshino1, Makoto Ariyoshi1, Yoshifumi Okawa1, Shuhei Tateishi1, Kazunori Ono1, Motoki Uchihashi1, Kuniyoshi Fukai1, Eri Iwai-Kanai1,2, Satoaki Matoba3.   

Abstract

Failing heart loses its metabolic flexibility, relying increasingly on glucose as its preferential substrate and decreasing fatty acid oxidation (FAO). Peroxisome proliferator-activated receptor α (PPAR-α) is a key regulator of this substrate shift. However, its role during heart failure is complex and remains unclear. Recent studies reported that heart failure develops in the heart of myosin heavy chain-PPAR-α transgenic mice in a manner similar to that of diabetic cardiomyopathy, whereas cardiac dysfunction is enhanced in PPAR-α knockout mice in response to chronic pressure overload. We created a pressure-overload heart failure model in mice through transverse aortic constriction (TAC) and activated PPAR-α during heart failure using an inducible transgenic model. After 8 wk of TAC, left ventricular (LV) function had decreased with the reduction of PPAR-α expression in wild-type mice. We examined the effect of PPAR-α induction during heart failure using the Tet-Off system. Eight weeks after the TAC operation, LV construction was preserved significantly by PPAR-α induction with an increase in PPAR-α-targeted genes related to fatty acid metabolism. The increase of expression of fibrosis-related genes was significantly attenuated by PPAR-α induction. Metabolic rates measured by isolated heart perfusions showed a reduction in FAO and glucose oxidation in TAC hearts, but the rate of FAO preserved significantly owing to the induction of PPAR-α. Myocardial high-energy phosphates were significantly preserved by PPAR-α induction. These results suggest that PPAR-α activation during pressure-overloaded heart failure improved myocardial function and energetics. Thus activating PPAR-α and modulation of FAO could be a promising therapeutic strategy for heart failure.NEW & NOTEWORTHY The present study demonstrates the role of PPAR-α activation in the early stage of heart failure using an inducible transgenic mouse model. Induction of PPAR-α preserved heart function, and myocardial energetics. Activating PPAR-α and modulation of fatty acid oxidation could be a promising therapeutic strategy for heart failure.
Copyright © 2017 the American Physiological Society.

Entities:  

Keywords:  PPAR-α; energy metabolism; fatty acid oxidation; heart failure

Mesh:

Substances:

Year:  2016        PMID: 28011586     DOI: 10.1152/ajpheart.00553.2016

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  30 in total

1.  Statistical considerations in reporting cardiovascular research.

Authors:  Merry L Lindsey; Gillian A Gray; Susan K Wood; Douglas Curran-Everett
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-07-20       Impact factor: 4.733

2.  Histone methyltransferase Smyd1 regulates mitochondrial energetics in the heart.

Authors:  Junco S Warren; Christopher M Tracy; Mickey R Miller; Aman Makaju; Marta W Szulik; Shin-Ichi Oka; Tatiana N Yuzyuk; James E Cox; Anil Kumar; Bucky K Lozier; Li Wang; June García Llana; Amira D Sabry; Keiko M Cawley; Dane W Barton; Yong Hwan Han; Sihem Boudina; Oliver Fiehn; Haley O Tucker; Alexey V Zaitsev; Sarah Franklin
Journal:  Proc Natl Acad Sci U S A       Date:  2018-07-30       Impact factor: 11.205

3.  IRX1 hypermethylation promotes heart failure by inhibiting CXCL14 expression.

Authors:  Longhuan Zeng; Nanyuan Gu; Jiayi Chen; Guangyong Jin; Yongke Zheng
Journal:  Cell Cycle       Date:  2019-10-22       Impact factor: 4.534

4.  Metabolic remodeling of substrate utilization during heart failure progression.

Authors:  Liang Chen; Jiangping Song; Shengshou Hu
Journal:  Heart Fail Rev       Date:  2019-01       Impact factor: 4.214

Review 5.  Targeting fatty acid metabolism for fibrotic disorders.

Authors:  Seonghwan Hwang; Ki Wung Chung
Journal:  Arch Pharm Res       Date:  2021-10-18       Impact factor: 4.946

6.  Cardiomyocyte peroxisome proliferator-activated receptor α is essential for energy metabolism and extracellular matrix homeostasis during pressure overload-induced cardiac remodeling.

Authors:  Xia Wang; Xin-Xin Zhu; Shi-Yu Jiao; Dan Qi; Bao-Qi Yu; Guo-Min Xie; Ye Liu; Yan-Ting Song; Qing Xu; Qing-Bo Xu; Frank J Gonzalez; Jie Du; Xiao-Min Wang; Ai-Juan Qu
Journal:  Acta Pharmacol Sin       Date:  2021-08-10       Impact factor: 7.169

7.  Direct Cardiac Actions of the Sodium Glucose Co-Transporter 2 Inhibitor Empagliflozin Improve Myocardial Oxidative Phosphorylation and Attenuate Pressure-Overload Heart Failure.

Authors:  Xuan Li; Qingguo Lu; Yunguang Qiu; Jussara M do Carmo; Zhen Wang; Alexandre A da Silva; Alan Mouton; Ana C M Omoto; Michael E Hall; Ji Li; John E Hall
Journal:  J Am Heart Assoc       Date:  2021-03-13       Impact factor: 5.501

Review 8.  PPAR control of metabolism and cardiovascular functions.

Authors:  David Montaigne; Laura Butruille; Bart Staels
Journal:  Nat Rev Cardiol       Date:  2021-06-14       Impact factor: 32.419

9.  Inhibition of the canonical Wnt signaling pathway by a β-catenin/CBP inhibitor prevents heart failure by ameliorating cardiac hypertrophy and fibrosis.

Authors:  Thanachai Methatham; Shota Tomida; Natsuka Kimura; Yasushi Imai; Kenichi Aizawa
Journal:  Sci Rep       Date:  2021-07-21       Impact factor: 4.379

Review 10.  The Role of Metabolism in Heart Failure and Regeneration.

Authors:  Jiyoung Bae; Wyatt G Paltzer; Ahmed I Mahmoud
Journal:  Front Cardiovasc Med       Date:  2021-07-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.